Levi & Korsinsky Investigates Procept BioRobotics After USD 17.4 Million Revenue Shortfall

Reuters03-19
Levi & Korsinsky Investigates Procept BioRobotics After USD 17.4 Million Revenue Shortfall
  • Levi & Korsinsky is investigating Procept BioRobotics over statements tied to a USD 325.5 million revenue target that was followed by reported revenue of USD 308.1 million.
  • The firm said CFO Kevin Waters reaffirmed the revenue target and referenced handpiece average selling prices of about USD 3,200.
  • According to the investigation notice, Procept had implemented a pricing initiative that removed bulk-purchase discounts, which the firm said reduced realized average selling prices.
  • The notice said the revenue shortfall was followed by a share-price drop of more than 15%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190900PRIMZONEFULLFEED9674784) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment